Table 1.
Vaccination with live attenuated rVSV-S vaccine protects mice from challenge with SARS-CoV
| Intervention group | Mouse number | Pre-challenge neutralizing antibody titer in serum (log2)a | Virus titer in lungsb | Mean maximum change in weight, on day 7 (%)c |
|---|---|---|---|---|
| SARS-CoV | 1 | 5.5 | ≤1.5d | |
| 2 | 7.0 | ≤1.5 | ||
| 3 | 7.7 | ≤1.5 | ||
| 4 | 5.3 | ≤1.5 | ||
| Mean ≤ 1.5 | +0.5 | |||
| rVSV-S | 5 | ≤2e | 4.2 | |
| 6 | 3 | 3.7 | ||
| 7 | 3 | 3.4 | ||
| 8 | 3 | ≤1.5 | ||
| Mean 3.2 ± 0.60 | +0.5 | |||
| rVSV | 9 | ≤2 | 7.7 | |
| 10 | ≤2 | 7.4 | ||
| 11 | ≤2 | 7.9 | ||
| 12 | ≤2 | 7.9 | ||
| Mean 7.8 ± 0.12 | −10 | |||
a
Log-transformed reciprocal mean SARS-CoV-specific neutralizing antibody titer.
b
Viral titers expressed as log10 TCID50/g tissue, p ≤ 0.0001 SARS-CoV compared to rVSV control and p = 0.0003 for rVSV-S compared to rVSV control, day 2 post-challenge.
c
Expressed as percent change in weight from weight on day of challenge (day 0).
d
Virus not detected, this value is the lower limit of virus detection.
e
Neutralizing antibody not detected, this value is at the lower limit of detection.